Charles N. York II Sells 10,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Rating) CFO Charles N. York II sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $20.05, for a total transaction of $200,500.00. Following the completion of the sale, the chief financial officer now directly owns 321,365 shares in the company, valued at $6,443,368.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Day One Biopharmaceuticals Trading Up 15.6 %

DAWN stock traded up $3.19 during midday trading on Friday, reaching $23.64. 932,724 shares of the company’s stock traded hands, compared to its average volume of 842,862. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $5.44 and a fifty-two week high of $28.70. The business has a 50-day moving average price of $15.39 and a two-hundred day moving average price of $12.69.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.09). On average, analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2 EPS for the current year.

Wall Street Analyst Weigh In

DAWN has been the topic of several research analyst reports. Wedbush raised their target price on shares of Day One Biopharmaceuticals from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, June 13th. Piper Sandler lifted their price target on shares of Day One Biopharmaceuticals from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, June 20th.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds have recently made changes to their positions in DAWN. New York State Common Retirement Fund purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $137,000. Canaan Partners XI LLC purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $162,832,000. Northern Trust Corp raised its stake in shares of Day One Biopharmaceuticals by 5.7% during the fourth quarter. Northern Trust Corp now owns 103,677 shares of the company’s stock valued at $1,747,000 after purchasing an additional 5,578 shares during the period. ProShare Advisors LLC purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $188,000. Finally, Alps Advisors Inc. purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $1,208,000. Hedge funds and other institutional investors own 79.02% of the company’s stock.

About Day One Biopharmaceuticals

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Featured Articles

Insider Buying and Selling by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.